Fulton Financial (FULT) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +27.91%. A quarter ago, it was expected that this financial holding company would post earnings of $0.44 per share when it actually produced earnings of $0.52, delivering a surprise of +18.18%. Over the last four ...

Group 1 - Hancock Whitney (HWC) reported quarterly earnings of $1.37 per share, exceeding the Zacks Consensus Estimate of $1.34 per share, and up from $1.31 per share a year ago, representing an earnings surprise of +2.24% [1] - The company posted revenues of $375.48 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.14%, and an increase from year-ago revenues of $359.6 million [2] - Hancock Whitney shares have increased approximately 10.1% since the beginning of the year, outperforming the S&P 500's gain of 6.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.36 on revenues of $384.34 million, and for the current fiscal year, it is $5.53 on revenues of $1.51 billion [7] - The Zacks Industry Rank for Banks - Southeast is currently in the top 24% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - FVCBankcorp, another company in the same industry, is expected to report quarterly earnings of $0.28 per share, reflecting a year-over-year change of +21.7% [9]

Core Viewpoint - Investors are seeking growth stocks that can deliver above-average growth and exceptional returns, but identifying such stocks is challenging due to inherent volatility and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is crucial for investors, with double-digit growth being a strong indicator of future stock price gains [3] - Harmony Biosciences has a historical EPS growth rate of 11.7%, with projected EPS growth of 22.5% this year, surpassing the industry average of 19.1% [4] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without external financing [5] - Harmony Biosciences has a year-over-year cash flow growth of 10%, significantly higher than the industry average of -4.7% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 25.7%, compared to the industry average of 4.1% [6] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [7] - Current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month [8] Group 5: Overall Assessment - Harmony Biosciences has achieved a Growth Score of B and a Zacks Rank 2, indicating positive earnings estimate revisions and potential for outperformance [9]

Core Viewpoint - Penguin Solutions, Inc. (PENG) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price momentum [1][2]. Earnings Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism about the company's earnings prospects, which is expected to be mirrored in the stock price [2]. - For the current quarter, the earnings estimate is $0.37 per share, showing no year-over-year change, but the Zacks Consensus Estimate has increased by 18.92% due to two upward revisions [6]. - For the full year, the earnings estimate is $1.85 per share, representing a 48.0% increase from the previous year, with the consensus estimate rising by 15.21% following two upward revisions [7][8]. Zacks Rank - Penguin Solutions, Inc. currently holds a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts in revising earnings estimates upward, which historically correlates with stock outperformance [3][9]. - Stocks with Zacks Rank 1 and 2 have shown significant outperformance compared to the S&P 500 [9]. Stock Performance - The stock has gained 27.5% over the past four weeks, suggesting investor confidence in the company's earnings growth prospects [10].

Core Insights - T. Rowe Price (TROW) shows potential as a portfolio addition due to notable revisions in earnings estimates, with an improving earnings outlook [1][10] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively influence its stock price [2][9] Current-Quarter Estimate Revisions - The current quarter's earnings estimate is projected at $2.08 per share, indicating a year-over-year decline of 8.0% [6] - Over the past 30 days, the Zacks Consensus Estimate for T. Rowe has increased by 7.67%, with four estimates moving higher and one lower [6] Current-Year Estimate Revisions - For the full year, the earnings estimate stands at $8.77 per share, reflecting a year-over-year decrease of 6.0% [7] - Recent trends show five upward revisions for the current year, with no negative revisions, resulting in a 6.2% increase in the consensus estimate [7][8] Zacks Rank and Performance - T. Rowe Price has achieved a Zacks Rank 2 (Buy) due to favorable estimate revisions, which is a reliable indicator for investors [9] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9] Bottom Line - The stock has gained 9.7% over the past four weeks, driven by solid estimate revisions, suggesting that earnings growth prospects may lead to further stock price increases [10]

Company Overview - Vertex (VERX) shares increased by 5% to close at $36.21, following a notable trading volume that exceeded typical levels, contrasting with a 6.6% loss over the past four weeks [1] - The company is benefiting from the rising adoption of e-invoicing mandates and cloud migration within the enterprise sector [1] Earnings Expectations - Vertex is projected to report quarterly earnings of $0.14 per share, reflecting a year-over-year decline of 6.7%, while revenues are expected to reach $184.25 million, marking a 14.4% increase from the previous year [2] - The consensus EPS estimate for Vertex has been revised 3% lower in the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] Industry Context - Vertex operates within the Zacks Internet - Software industry, where another company, Exodus Movement, Inc. (EXOD), saw its stock rise by 2.1% to $33.7, with a 5.2% return over the past month [3] - Exodus Movement, Inc. has an unchanged consensus EPS estimate of -$0.17, representing a 54.1% improvement from the previous year, but currently holds a Zacks Rank of 5 (Strong Sell) [4]

Core Viewpoint - Marex Group PLC (MRX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting the stock price [4]. Company Performance Indicators - For the fiscal year ending December 2025, Marex Group PLC is expected to earn $3.35 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.4% over the past three months [8]. - The upgrade to Zacks Rank 2 places Marex Group PLC in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The system maintains a balanced distribution of ratings, ensuring that only the top 5% of stocks receive a "Strong Buy" rating, while the next 15% receive a "Buy" rating [9].

Core Viewpoint - ACNB has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - For the fiscal year ending December 2025, ACNB is expected to earn $4.43 per share, with a 14.4% increase in the Zacks Consensus Estimate over the past three months [8]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of stocks, and changes in these estimates can lead to significant buying or selling activity, impacting stock prices [4]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the system [7].

Core Viewpoint - Rapt Therapeutics has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Rapt Therapeutics indicates a positive outlook on its earnings, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly influenced by institutional investors [5]. - For Rapt Therapeutics, the rising earnings estimates and the rating upgrade suggest an improvement in the company's underlying business, which should drive the stock price higher [6]. Historical Performance of Zacks Rank - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Rapt Therapeutics to a Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Recent Earnings Estimate Trends - For the fiscal year ending December 2025, Rapt Therapeutics is expected to earn -$2.29 per share, unchanged from the previous year, but analysts have raised their estimates significantly, with a 72.2% increase in the Zacks Consensus Estimate over the past three months [9].

Core Viewpoint - Cellectar Biosciences, Inc. (CLRB) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to significant buying or selling activity that affects stock prices [4]. Company Performance and Outlook - The upgrade reflects an improvement in Cellectar Biosciences' underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for Cellectar Biosciences has increased by 26.1% [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7]. - Cellectar Biosciences' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].